SystemAge Test from Generation Lab

The $499 one-time price includes a broad 21-system methylation report, action plan, and provider consultation labeled beta. Value depends on the user's interest in biological-age tracking because the report is informational, does not replace conventional testing, and has not demonstrated product-level clinical utility for diagnosing or managing the individual systems it estimates.

The product advertises more than 460 methylation biomarkers, 21 systems, sex-specific results, a whole-body SystemAge estimate, and functional SystemAge outputs. This is broad coverage within the provider's aging model, but it is not broad conventional clinical testing and should not be interpreted as direct measurement of all 21 organ systems.

The report is directly relevant to users seeking a DNA-methylation-based biological-age estimate across the provider's 21-system framework. It is not a direct assessment of organ function, disease, or treatment response, and the provider's terms describe the observations as informational and preclinical.

The digital report, action plan, provider consultation labeled beta, and ongoing support may help users navigate the output. Interpretability is limited by the model-derived nature of system-age estimates, preclinical framing, lack of published product-level clinical thresholds, and the risk that users may mistake biological-age estimates for organ diagnoses.

The provider documents an at-home blood collection, contracted CLIA-certified laboratory processing, more than 460 CpG biomarkers, a defined BioNoise framework, and high provider-reported same-sample triplicate agreement. The reviewed materials do not publish independent product-level analytical validation, calibration error, failure rates, or reproducibility across contracted laboratories.

The product can be ordered online, collected at home with a needle-free upper-arm device, returned with prepaid shipping, and viewed digitally. The multi-week post-receipt wait, minimum blood-volume requirement, possible recollection, and international distributor routing add practical friction. New York residents are excluded: the binding test consent (revised 2026-07-29, reviewed fresh 2026-09-15) requires each test-taker to certify "I am not a resident of the state of New York," so no New York physician-order route is supported by current evidence.

The current privacy and research documents identify specimens, health information, reports, fulfillment partners, contracted laboratories, clinician sharing, optional research participation, deletion rights, and research withdrawal rules. The absence of a fixed general retention period, indefinite deidentified-data retention, broad third-party research collaboration, and inability to retrieve prior aggregate research use support a conservative score.

Generation Lab publishes the current one-time, subscription, and bundle prices, sample route, minimum specimen volume in consent, biomarker count, system count, method description, legal limits, privacy policy, optional research consent, and fulfillment partner. Transparency is reduced by unnamed contracted laboratories, an unresolved New York access conflict, and promotional accuracy claims that are not supported by product-specific independent validation on the reviewed pages.